Form 8-K - Current report:
SEC Accession No. 0001193125-20-279883
Filing Date
2020-10-28
Accepted
2020-10-28 16:33:02
Documents
14
Period of Report
2020-10-28
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d40485d8k.htm   iXBRL 8-K 48668
2 EX-99.1 d40485dex991.htm EX-99.1 23458
6 GRAPHIC g40485g1029005420838.jpg GRAPHIC 3726
  Complete submission text file 0001193125-20-279883.txt   206959

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ccxi-20201028.xsd EX-101.SCH 3083
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ccxi-20201028_lab.xml EX-101.LAB 17375
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ccxi-20201028_pre.xml EX-101.PRE 10962
7 EXTRACTED XBRL INSTANCE DOCUMENT d40485d8k_htm.xml XML 3231
Mailing Address 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Business Address 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043 650-210-2900
ChemoCentryx, Inc. (Filer) CIK: 0001340652 (see all company filings)

EIN.: 943254365 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35420 | Film No.: 201269114
SIC: 2834 Pharmaceutical Preparations